By Fineline Cube 
Roche AG (SWX: ROP, OTCMKTS: RHHBY) reported first-quarter 2026 group sales of CHF 14.7 billion ($16.17 billion), representing 6% growth at constant exchange rates (CER). The company noted that reported sales declined 5% in Swiss francs due to significant currency headwinds from a stronger franc.
Financial Performance Summary
| Item | Detail |
|---|---|
| Reporting Period | Q1 2026 |
| Group Sales | CHF 14.7 billion ($16.17 billion) |
| Growth Rate | +6% CER (-5% reported) |
| Pharmaceuticals Division | CHF 11.5 billion (+7% CER) |
| Diagnostics Division | CHF 3.3 billion (+3% CER) |
Growth Drivers – Innovative Medicine Portfolio
- Key Products: Xolair (chronic hives/food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (eye diseases), Ocrevus (multiple sclerosis)
- Combined Sales: CHF 5.3 billion (+14% CER), representing 36% of total group sales
- Top Performers:
- Ocrevus: CHF 1.692 billion (+6%)
- Hemlibra: CHF 1.19 billion (+13%)
- Vabysmo: CHF 1.024 billion (+13%)
- Legacy Products: Avastin, Herceptin, and MABThera/Rituxan continued decline (-CHF 0.1 billion)
Regional Performance Highlights
| Region | Sales Change | Key Factors |
|---|---|---|
| United States | +5% | Strong uptake of Xolair, Hemlibra, Ocrevus, Vabysmo |
| Europe | -1% | Biosimilar competition and product transitions |
| Japan | +14% | Strong therapy uptake and third-party supply |
| International | +16% | China +14% driven by reimbursement inclusion |
Pipeline & Strategic Updates
- Clinical Data: Phase III results for fenebrutinib (MS), Gazyva/Gazyvaro (autoimmune kidney disease), Phase II data for petrelintide (obesity)
- Product Launches: CE mark for Elecsys NfL blood test, cobas MPX-E assay (4-in-1 screening test)
- Strategic Initiatives: AI factory for R&D expansion, acquisition of SAGA Diagnostics
Market Impact & Outlook
- Commercial Strategy: Continued shift toward newer, high-value therapies to offset biosimilar erosion
- Geographic Diversification: Growth in China and international markets remains a cornerstone strategy
- Full-Year Guidance:
- Mid single-digit sales growth
- High single-digit core EPS growth
- Continued dividend increases in Swiss francs
Forward‑Looking Statements
This brief contains forward-looking statements regarding Roche’s financial performance, pipeline development, and commercial expectations. Actual results may differ due to risks including market competition, regulatory changes, and currency fluctuations.-Fineline Info & Tech